Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEM-iSMART Sub-protocol B: dasatinib + venetoclax in pediatric relapsed/refractory leukemia or lymphoma with MAPK/SRC-pathway alterations
2022-501866-22-00Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of dasatinib and venetoclax in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum tolerated dose / recommended phase 2 dose and Best overall response rate. Planned start Aug 2025; status: authorised.
02
Drugs
dasatinibvenetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2022-501866-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501866-22-00.